A study for a 34 year old man who takes Bleomycin Sulfate - from FDA reports

Summary

965 males aged 34 (±5) who take the same drug are studied. This is a personalized study for a 34 year old male patient who has Testicular Cancer. The study is created by eHealthMe based on reports from FDA.



How the study uses the data?

The study is based on gender, age, active ingredients of any drugs used. Other drugs that have the same active ingredients (e.g. generic drugs) are considered.

What are the drugs?

What are the conditions?

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.


On Jan, 12, 2019

965 males aged 34 (±5) who take Bleomycin Sulfate are studied.


Number of reports submitted per year:

Bleomycin Sulfate for a 34-year old man.

Information of the patient in this study:

  • Age: 34
  • Gender: male
  • Conditions: Testicular Cancer
  • Drugs taken:
    • Bleomycin Sulfate (bleomycin sulfate)

eHealthMe real world results:

Most common side effects over time

< 1 month:
  1. Fever
  2. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  3. Diarrhea
  4. Heart attack
  5. Leukopenia (less number of white blood cells in blood)
  6. Pulmonary embolism (blockage of the main artery of the lung)
  7. Red blood cell count decreased
  8. Blood creatinine increased
  9. Weight decreased
  10. Malignant neoplasm progression (cancer tumour came back)
1 - 6 months:
  1. Nausea (feeling of having an urge to vomit)
  2. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  3. Fatigue (feeling of tiredness)
  4. Nausea and vomiting
  5. Breathing difficulty
  6. Headache (pain in head)
  7. Diarrhea
  8. Back pain
  9. Idiopathic pulmonary fibrosis (chronic lung disease)
  10. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
6 - 12 months:
  1. Guillain-barre syndrome (the body's immune system attacks its peripheral nervous system)
  2. Hypoaesthesia (reduced sense of touch or sensation)
  3. Demyelinating polyneuropathy (disorder that affects the nerves outside of the brain and spinal cord (peripheral nerves))
  4. Areflexia (absence of a reflex)
  5. Peripheral nerve injury
  6. Urinary retention (the inability to completely or partially empty the bladder)
  7. Hypotonia (low muscle tone)
  8. Hodgkin's disease recurrent (cancer originating from white blood cells -recurrent)
  9. Quadriplegia (a four limb paralysis)
  10. Papillary thyroid cancer
1 - 2 years:
  1. Myelodysplastic syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged)
  2. Death
  3. Idiopathic pulmonary fibrosis (chronic lung disease)
  4. Hepatic neoplasm (liver tumour)
  5. Metastases to spine (cancer spreads to spine)
  6. Pleural fibrosis (formation of fibrous tissue in lung)
  7. Chromosome abnormality (abnormal gene structure pattern)
  8. Thrombocytopenia (decrease of platelets in blood)
  9. Anaemia (lack of blood)
  10. Neoplasm recurrence (reoccurrence of tumour)
2 - 5 years:
n/a
5 - 10 years:
n/a
10+ years:
n/a
not specified:
  1. Fever
  2. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
  3. Diarrhea
  4. Heart attack
  5. Acute myocardial infarction (acute heart attack)
  6. Nausea (feeling of having an urge to vomit)
  7. Thrombocytopenia (decrease of platelets in blood)
  8. Hodgkin's lymphoma (cancer originating from white blood cells)
  9. Abdominal pain
  10. Pulmonary embolism (blockage of the main artery of the lung)

Top conditions involved for these people *:

  1. Hodgkin's Lymphoma (cancer originating from white blood cells): 182 people, 18.86%
  2. Testis Cancer (testes cancer): 169 people, 17.51%
  3. Germ Cell Cancer : 63 people, 6.53%
  4. Chemotherapy : 31 people, 3.21%
  5. Hiv Infection : 26 people, 2.69%
  6. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 26 people, 2.69%
  7. Testicular Germ Cell Cancer (germ cell cancer of testes): 21 people, 2.18%
  8. Preventive Health Care : 19 people, 1.97%
  9. Lymphoma (cancer that begins in immune system cells): 19 people, 1.97%
  10. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 16 people, 1.66%

Top co-used drugs for these people *:

  1. Etoposide (384 people, 39.79%)
  2. Cisplatin (328 people, 33.99%)
  3. Dacarbazine (116 people, 12.02%)
  4. Vinblastine Sulfate (93 people, 9.64%)
  5. Cyclophosphamide (87 people, 9.02%)
  6. Adriamycin Pfs (72 people, 7.46%)
  7. Neulasta (52 people, 5.39%)
  8. Prednisone (52 people, 5.39%)
  9. Methotrexate (50 people, 5.18%)
  10. Ifosfamide (45 people, 4.66%)

* Some reports may have incomplete information.

What is next?

You are not alone:




Related studies:



FDA reports used in this study



Recent updates

Recent general studies
Recent personal studies


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.